Key result
VK 744 prolonged the kaolin-stypven time and inhibited ADP aggregation in human male volunteers, but side effects prevented continuation of the trial.
Why the study?
Does VK 744 inhibit platelet aggregation in vivo in human male volunteers?
RCT
Coded
Does VK 744 inhibit platelet aggregation in vivo in human male volunteers?
VK 744 inhibits platelet aggregation in vivo, but its clinical utility is limited by intolerable side effects.
VK 744 — a dipyridamole analogue — is an inhibitor of primary aggregation of platelets in vitro. In this paper we describe the in vivo effects in human male volunteers. A dose of 1500 mg VK 744 prolonged the kaolin‐stypven time and inhibited ADP aggregation. Administration of 500 mg three times daily during 48 hrs in a paired coded investigation produced a slightly significant prolongation of the kaolin‐stypven time. Side effects prevented continuation of the trial. The inhibition by indomethacin was not enhanced by combination with VK 744.
No takes yet. Share an insight, caveat, or question.
Sixma et al. (1972) reported an RCT. VK 744 was evaluated on Kaolin-stypven time. VK 744 prolonged the kaolin-stypven time and inhibited ADP aggregation in human male volunteers, but side effects prevented continuation of the trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: